Search

Tamoxifen, a selective estrogen receptor modulator, remains a standard of endocrine therapy for estrogen receptor alpha (ERα) positive breast cancer (Goldhirsch et al., 2013). Despite well-known advantages of tamoxifen treatment, approximately one third of patients experience a relapse or disease progression due to tamoxifen resistance (Osborne et al., 2011). Identification of additional molecular markers associated with both ER genomic and non-genomic pathways could be very useful to help identify patients who will likely benefit from such endocrine treatment. The aim of the present study was to evaluate the influence of the distribution pattern of ERαexpression as well as ESR1, TGF-βR1and IGF-1Rsingle nucleotide polymorphisms (SNPs) and the expression of growth factors receptors on disease progression in breast cancer patients of Russian Western Siberian population treated by adjuvant tamoxifen.